priors.science/reviews/alk-and-ros1-inhibitors

ALK and ROS1 Inhibitors

The current evidence on 23 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

23claims tracked
88primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
8 Established · 13 Likely · 2 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Next-generation ALK tyrosine kinase inhibitors vs crizotinib progression-free survivalAlkinlEstablished95%8
Next-generation ALK tyrosine kinase inhibitors vs crizotinib for brain metastasesCNSEstablished91%5
Immune checkpoint inhibitor monotherapy in ALK-positive non-small cell lung cancerIciEstablished89%4
Crizotinib objective response rate in ROS1-positive non-small cell lung cancerRos1Established89%6
Lorlatinib hyperlipidemia vs second-generation inhibitorsSafetyEstablished89%7
Adjuvant alectinib disease-free survival in ALK-positive non-small cell lung cancerAlkinlEstablished86%6
Crizotinib in ALK-positive inflammatory myofibroblastic tumourEmergingEstablished86%4
ALK kinase domain mutations and second-generation resistanceResistEstablished86%4
Lorlatinib central nervous system adverse effectsSafetyLikely84%4
RNA-based vs DNA-based next-generation sequencing for fusionsBiomarkLikely82%5
Sequential immune checkpoint inhibitor then ALK tyrosine kinase inhibitor toxicitySafetyLikely82%4
Liquid biopsy sensitivity for fusionsBiomarkLikely81%5
ALK inhibitors in anaplastic large cell lymphomaEmergingLikely81%3
ALK-positive non-small cell lung cancer immunosuppressive tumour microenvironmentIciLikely77%4
Compound ALK mutations and lorlatinib resistanceResistLikely77%3
Repotrectinib progression-free survival in tyrosine kinase inhibitor-naive ROS1-positive diseaseRos1Likely77%4
Lorlatinib superior intracranial controlCNSLikely76%4
Off-target bypass in ALK tyrosine kinase inhibitor resistanceResistLikely76%4
Repotrectinib after crizotinib in ROS1-positive diseaseRos1Likely75%4
Lorlatinib progression-free survival advantage over alectinibAlkinlLikely72%4
Next-generation ALK tyrosine kinase inhibitors in inflammatory myofibroblastic tumour after crizotinibEmergingLikely70%3
ALK tyrosine kinase inhibitor plus immune checkpoint inhibitor combinationIciUncertain68%5
EML4-ALK variant 3 and resistance mutation riskResistUncertain59%5
Track ALK and ROS1 Inhibitors.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.